

Title: Malignant Hyperthermia				
Document #: 6489	ocument #: 6489 Issuing Authority: BP Clinical Programs/Chief Nurse			
	Executive, Administration			
Last Revised Date: 11/29/2019		Version Number: 2.1 (Current)		

PURPOSE:

This policy outlines the safe management of patients with known risk for Malignant Hyperthermia (MH) and the management of a MH crisis at the Brant Community Healthcare System (BCHS).

POLICY STATEMENT:

Malignant Hyperthermia can present whenever inhalation anaesthetics and/or succinylcholine are used.

While most cases of MH occur during general anaesthesia, it has occurred up to 12 hours post anaesthetic.

Those patients with a family history of MH who have had previous anaesthetics without a problem **are still at risk**. Deaths have occurred even though patients have undergone multiple prior uneventful surgeries.

DEFINITION (S):

Malignant Hyperthermia:

A potentially fatal, rare genetic disorder characterized by a hypermetabolic state usually triggered by potent halogenated inhalation anesthetic agents and depolarizing skeletal muscle relaxants (ORNAC, 2017) Early Signs of MH include hypercarbia, sinus tachycardia, masseter muscle rigidity (MMR), generalized muscle rigidity and/or oxygen desaturation.

PROCEDURE:

- 1) Care of the Patient Pre-operatively (Surgical and/or Labour and Delivery Patients):
 - a. Perioperative registered nurses shall assess patients pre-operatively for possible MH risk factors such as a family history of a severe reaction or unexplained death during anesthesia.
 - b. Patients with a known risk for MH who require surgery will be scheduled as the first case in the morning when possible.
 - c. To ensure an adequate supply of equipment and drugs, **only one (1) patient with a known risk for MH should be scheduled per day**. If the necessity arises for more than one patient with known risk for MH to be scheduled per day, the subsequent surgeries will be cancelled should a patient experience a MH crisis.
- 2) Care of the Post-Operative Patient with Known Risk for Malignant Hyperthermia Crisis:



Title: Malignant Hyperthermia				
Document #: 6489	Document #: 6489 Issuing Authority: BP Clinical Programs/Chief Nurse			
	Executive, Administration			
Last Revised Date: 11/29/2019		Version Number: 2.1 (Current)		

- a. The patient should be transferred from the Operating Room (OR) on the hyper/hypothermia blanket, on a hospital bed. In the event that the patient arrived for surgery on a stretcher, the Operating Room Assistant (ORA) shall deliver a bed to the OR for post-operative care of the MH patient.
- b. The OR/Labour and Delivery (L&D) MH cart and hypothermia blanket will accompany the postoperative patient from the OR to the Post Anaesthetic Care Unit (PACU) for the recovery phase.
- c. Vital signs (including temperature) will be monitored every fifteen (15) minutes in PACU and L&D until discharge criteria are met or as specified by the Anaesthesiologist.
- d. If the anesthetic was uneventful, and no anesthetic drugs that trigger MH were used, continue to monitor the patient for a total of two (2) hours in PACU, L&D and Day Surgery.

3) Post-Operative Care Of the Day Surgery Patient with Known Risk for Malignant Hyperthermia Crisis:

- a. Discharge of day surgery patients may be possible after two (2) hours, providing all other discharge criteria are met (Malignant Hyperthermia Association, 2015).
- b. An intravenous catheter will remain in situ until discharge for day surgery patients.

4) Post-Operative Care Of the In-Patient with Known Risk for Malignant Hyperthermia Crisis:

- a. Patients with known risk for MH may be cared for post-operatively on a clinical unit.
- b. On the clinical unit, vital signs (including temperature) will be monitored per routine vital sign frequency.
- c. Intravenous (IV) catheter will remain in situ for at least 12 hours postoperatively.
- d. The Anaesthesiologist will be Notified at Anytime During the First 24 Hours if Any of the Following Symptoms Develop:
 - i. Tachycardia is present or arrhythmia develops
 - ii. Muscle rigidity develops
 - iii. Oxygen saturation decreases (less than 95%) or oxygen requirements increase
 - iv. Temperature increases 0.5 degrees centigrade in any 15 minute period
 - v. Patient becomes tachypnic, flushed or diaphoretic



Title: Malignant Hyperthermia			
Document #: 6489	Issuing Authority: BP Clinical Programs/Chief Nurse		
	Executive, Administration		
Last Revised Date: 11/29/2019		Version Number: 2.1 (Current)	

5) Malignant Hyperthermia Crisis in the Operating Room (Intraoperatively):

- a. The circulating nurse shall inform the OR most responsible nurse (MRN) that a MH crisis is occurring.
 - i. **During off shifts call Code BLUE**. The code team will assist as required.
- b. The OR MRN shall assign personnel to bring:
 - i. **MH cart** to the operating room suite (accessed through the OR and/or L&D)
 - ii. Insulin and cold normal saline intravenous bags from the refrigerator, and ice from the freezer or ice machine
 - iii. Code Cart
 - iv. Additional staff as required
- c. The Anaesthesiologist shall direct the treatment of the MH crisis.
- d. The Surgeon shall complete the surgery as quickly as possible, or will cover the operative site.
- e. The OR circulating nurse shall obtain the Vapor- Clean (charcoal) filter from the MH cart and change the disposables. The charcoal filter attaches between the machine and the circuit.
- f. The "Malignant Hyperthermia Critical Intervention Record" will be utilized to record the details of the crisis.
- g. The "Malignant Hyperthermia Dantrolene Administration Record" will be utilized to record dantrolene administration.
- h. The OR MRN shall advise the Critical Care Unit (CCU) regarding potential CCU admission and name of patient's most responsible physician (MRP). The CCU Intensivist shall assume care of the patient on arrival to CCU.
- i. Following a MH crisis, the patient should be registered with Malignant Hyperthermia Investigation Unit in Toronto (refer to <u>http://pie.med.utoronto.ca/MH/MH_content/reportMH.html</u> for the most up to date form).

6) Malignant Hyperthermia Crisis Outside of the OR:

- a. In the event of a MH Crisis outside of the OR call Anaesthesiologist STAT and Code BLUE STAT.
- b. There are 36 vials of dantrolene (Dantrium) in hospital inventory.
 - i. 12 vials are kept in the OR EL1
 - ii. 12 vials in L&D on C3
 - iii. 12 vials in the CCU on D5
- c. The "Malignant Hyperthermia Critical Intervention Record" will be utilized to record the details of the crisis.



Title: Malignant Hyperthermia			
Document #: 6489	Issuing Authority: BP Clinical Programs/Chief Nurse		
	Executive, Administration		
Last Revised Date: 11/29/2019		Version Number: 2.1 (Current)	

- d. The "Malignant Hyperthermia Dantrolene Administration Record" will be utilized to record dantrolene administration.
- e. The MRN shall advise the Critical Care Unit (CCU) regarding potential CCU admission and name of patient's most responsible physician (MRP). The CCU Intensivist shall assume care of the patient on arrival to CCU.
- f. Following a MH crisis, the patient should be registered with Malignant Hyperthermia Investigation Unit in Toronto (refer to <u>http://pie.med.utoronto.ca/MH/MH_content/reportMH.html</u> for the most up to date form).

RELATED PRACTICES AND / OR LEGISLATIONS:

N/A

APPENDICES:

Appendix A – Preparation of the Operating Room for the Patient with Known or Suspected Malignant Hyperthermia

Appendix B – Contents of Malignant Hyperthermia Drug Box

Appendix C – Triggering Agents (not to be used) and Safe Agents (may be used)

- Appendix D Reconstitution of dantrolene sodium
- Appendix E Malignant Hyperthermia Cart Monthly Checklist
- Appendix F Malignant Hyperthermia Critical Intervention Record

Appendix G – Malignant Hyperthermia Dantrolene Administration Flowsheet

REFERENCES:

Association of periOperative Registered Nurses. (2008). AORN malignant hyperthermia guideline. *Perioperative standards and recommended practices*, 103-140.

- Berry, E.C. & Kohn, M. L. (1996). Operating room technique. Mosby: New York.
- Heggie, J. E. (2002). Malignant hyperthermia: Considerations for the general surgeon. *Canadian Journal of Surgery*, 45(5), 369-372.
- Hommertzheim, R., & Steinke, E., E. (2006). Malignant Hyperthermia: The perioperative nurse's role. *AORN Journal*, 83(1), 151-164.

Litman, R. S. (2018). Malignant hyperthermia: Clinical diagnosis and management of acute crisis. *Up to Date*. Retrieved from: https://www.uptodate.com/contents/malignant-hyperthermia-clinical-diagnosisand-management-of-acute-



Title: Malignant Hyperthermia			
Document #: 6489	Issuing Authority: BP Clinical Programs/Chief Nurse		
	Executive, Administration		
Last Revised Date: 11/29/2019		Version Number: 2.1 (Current)	

crisis?search=malignant%20hyperthermia&source=search_result&selectedTitle= 1~123&usage_type=default&display_rank=1

- Malignant hyperthermia. (2018). Retrieved from https://ghr.nlm.nih.gov/condition/malignant-hyperthermia
- McNeil, B. (2005). Malignant hyperthermia. *British Journal of Perioperative Nursing*, 15(9).
- Operating Room Nurses Association of Canada. (2017). *The ORNAC standards, guidelines, and position statements for perioperative registered nurses* (13th ed.).
- Riazi, S., Kraeya, N. & Hopkins, P.M. (2018). Updated guide for the management of malignant hyperthermia. *Canadian Journal of Anaesthesia*, 65(6), 709-721.
- Rosenberg, H. (2010). Malignant hyperthermia syndrome. Retrieved from https://www.mhaus.org/
- Toronto General Hospital Malignant Hyperthermia Investigation Unit. Malignant hyperthermia. (2012). Retrieved from http://pie.med.utoronto.ca/MH/index.htm




Title: Malignant Hyperthermia				
Document #: 6489	Document #: 6489Issuing Authority: BP Clinical Programs/Chief Nurse			
	Executive, Administration			
Last Revised Date: 11/29/2019		Version Number: 2.1 (Current)		

APPENDICES:

Appendix A – Preparation of the Operating Room for the Patient with Known or Suspected Malignant Hyperthermia

PROCEDURE: Set-up of OR Room

- MH cases (known or suspected) will be scheduled for 0800 hours and should be set up the night before whenever possible.
- Respiratory Therapist (RT):
 - Converts anaesthetic machine to vapour-free (refer to manufacturer's instructions for use).
 - All vaporizers are removed from the machine (i.e. sevoflurane, desflurane), and placed on a stainless steel table at the anesthetic end of the Operating Room.
 - Prepares anaesthetic machine with a new breathing circuit, re-breathing bag and mask. The anaesthetic machine is flushed with O2 on 100% for a minimum of fifteen (15) minutes (a sign is hung on the machine to identify as such).
 - Changes CO2 absorbent.
- Operating Room Assistants:
 - Brings MH cart into the OR suite.
 - Hangs MH sign on the OR door.
 - Places hyper/hypothermia blanket is on the OR table and set at 36°C but not turned on.
- Registered Nurses:
 - One circulating nurse will be assigned to the room.
 - ECG, BP, Pulse oximeter, 2 temperature probes will be used.
 - o Additional monitoring used at the discretion of the Anaesthesiologist.



Appendix B – Contents of Malignant Hyperthermia Drug Box

It is the responsibility of the OR circulating nurse and L&D MRN to ensure that all MH equipment is replaced and the MH cart is fully stocked. The MH cart shall be checked once per month and after use (See Appendix D).

	MALIGNANT HYPERTHERMIA DRUG BOX					
One (1) Mal	One (1) Malignant Hyperthermia kit to be located in the OR and one in L&D. Contents					
& expiry dat	es checked by Pharmacy on a monthly basis or after use.					
	CONTENTS					
12	dantrolene 20 mg IV vials in OR MH cart					
	(12 vials dantrolene in L&D & 12 vials in CCU = total of 36 vials)					
2	sterile water - 1000 mL bags (non-bacteriostatic agent)					
2	dextrose 50% - 50 mL preloaded syringes					
5	sodium bicarbonate 8.4% - 50 mL pre-loaded syringes					
1	propranolol 1 mg/mL 1 mL vial					
3	furosemide 40 mg/2 mL amps					
2	calcium chloride 10% - 1 g/10 mL pre loaded syringes					
3	lidocaine HCL 2% - 100 mg/5 mL					
	regular insulin – refrigerated					
5	Cornwall syringes (vented needle taped to package)					
5	60 mL luer lock syringes					
2	20 mL luer lock syringes					
1	Mini drip buretrol IV administration set					
1	Secondary IV medication administration set					
6	Arterial blood gas kits					
2	Blood tubes – 2 each yellow, blue, red, purple tops					
4	Millipore 0.22 um filters					
5	Each needles, gauge size: 16, 18, 21, 22					
4	Each IV catheters, gauge size: 24, 22, 20, 18, 16					
3	Cold saline 1000 mL – refrigerated					
1	dextrose 5% IV solution 250 mL bag					



Title: Malignant Hyperthermia				
Document #: 6489	Issuing Authority: BP Clinical Programs/Chief Nurse			
	Executive, Administration			
Last Revised Date: 11/29/2019		Version Number: 2.1 (Current)		

Appendix C – Triggering Agents (not to be used) and Safe Agents (may be used):

Triggering Agents: DO NOT USE

Drug Class	Examples Available at the BCHS				
All volatile inhalation anesthetics	sevoflurane				
	desflurane				
Depolarizing Muscle Relaxant	succinylcholine				

Safe Agents: May be Used (Not a comprehensive list)

Local anaesthetics	Non-depolarizing muscle relaxants such as:
Barbiturates	atracurium
Opioids	cisatracurium
nitrous oxide	mivacurium
propofol	pancuronium
Benzodiazepines	vecuronium
ketamine	rapacuronium
etomidate	rocuronium



Title: Malignant Hyperthermia			
Document #: 6489	Issuing Authority: BP Clinical Programs/Chief Nurse		
	Executive, Administration		
Last Revised Date: 11/29/2019		Version Number: 2.1 (Current)	

Appendix D – Reconstitution of dantrolene sodium


- Give 2.5 mg/kg body weight
- Add 60 mL of non-bacteriostatic sterile water to 1 vial of 20 mg dantrolene sodium
- Concentration of reconstituted dantrolene sodium is 0.33 mg/mL

WEIGHT of patient	5 kg	10 kg	15 kg	20 kg	25 kg	30 kg	35 kg	40 kg	45 kg
DOSAGE (2.5mg/kg)	12.5 mg	25.0 mg	37.5 mg	50 mg	62.5 mg	75 mg	87.5 mg	100 mg	112.5 mg
VOLUME of Reconstituted Solution	37.88 mL	75.76 mL	113.64 mL	151.52 mL	189.4 mL	227.27 mL	265.15 mL	303 mL	337.5 mL
Number of vials needed for reconstitution	1	2	2	3	4	4	5	5	6

DANTROLENE RECONSTITUTION CHART 20 mg/vial

WEIGHT of patient	50 kg	55kg	60 kg	65 kg	70 kg	75 kg	80 kg	85 kg	90 kg
DOSAGE (2.5mg/kg)	125 mg	137.5 mg	150 mg	162.25 mg	175 mg	187.5 mg	200 mg	212.5 mg	225 mg
VOLUME of Reconstituted Solution	378.79 mL	416.67 mL	454.55 mL	492.42 mL	530.3 mL	568.18 mL	606.06 mL	643.94 mL	675 mL
Number of vials needed for reconstitution	7	7	8	9	9	10	10	11	12

WEIGHT of patient	95 kg	100 kg	105 kg	110 kg	115 kg	120 kg	125 kg	130 kg	135 kg
DOSAGE (2.5mg/kg)	237.5 mg	250 mg	262.5 mg	275 mg	287.5 mg	300 mg	312.5 mg	325 mg	337.5 mg
VOLUME of Reconstituted Solution	719.7 mL	757.58 mL	795.45 mL	833.33 mL	871.21 mL	909.09 mL	946.97 mL	984.85 mL	1012.5 mL
Number of vials needed for reconstitution	12	13	14	14	15	15	16	17	17



Appendix E – Malignant Hyperthermia Cart Monthly Checklist

THE BRANTFORD GENERAL HOSPITAL- SURGICAL SUITE MALIGNANT HYPERTHERMIA CART – MONTHLY CHECKLIST												
MALIGNANT THE EXTREMINA CART - MONTHET CHECKEIST												
HYPERTHERMIA	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEPT	ОСТ	NOV	DEC
KIT - CONTENTS	JAN	ILD				301	JUL	AUG	JLF I	001	NOV	DLC
TOP OF CART												
Malignant hyperthermia												
caution signs												
Malignant hyperthermia												
blanket												
CO2 absorbent												
Portable thermometer												
Rectal probe												
DRAWER 1												
12 – dantrolene sodium												
20 mg vials												
2 pairs - Vapor-Clean												
charcoal filters												
2 – dextrose 50% 50												
mL syringes												
5 – 50 mL sodium												
bicarbonate 8.4%												
1 – Mini drip buretrol												
solution set												
1 – Secondary												
medication set												
6 – Arterial blood gas												
kits or ABG syringes												
5 – each needles,												
gauge size: 16, 18, 21,												
22												
4 – each IV catheters,												
gauge size: 16, 18, 20, 22, 24												
2 – each of Blood tubes												
 yellow, blue, red, 												
purple tops												
4 – Millipore 0.22 filters												
4 – Specimen bags												



Title: Malignant Hyperthermia							
Document #: 6489	Issuing Authori	ty: BP Clinical Programs/Chief Nurse					
	Executive, Admi	nistration					
Last Revised Date: 11/29/20	19	Version Number: 2.1 (Current)					

	THE BRANTFORD GENERAL HOSPITAL- SURGICAL SUITE MALIGNANT HYPERTHERMIA CART – MONTHLY CHECKLIST											
DRAWER 2	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEPT	ОСТ	NOV	DEC
2 – sterile water 1000 mL IV bags (non-bacteriostatic)												
1 – propranolol 1 mg/mL												
3 – furosemide 40 mg/2 mL												
1 – lidocaine HCL 2% 100 mg/ 5 mL												
2 – calcium chloride 10% 1 g/10 mL pre- loaded syringes												
1 – dextrose 5% IV solution 250 mL bag												
2 – Cornwall syringes (with vented 16 gauge needle taped to pkg) OR												
2 – Transfer sets 12 – 60 mL luer lock syringes												
12 – Mini-spikes												
2 – 20 mL luer lock syringes												




Title: Malignant Hyperthermia							
Document #: 6489	Issuing Authori	ty: BP Clinical Programs/Chief Nurse					
	Executive, Admi	nistration					
Last Revised Date: 11/29/20	19	Version Number: 2.1 (Current)					

	THE BRANTFORD GENERAL HOSPITAL- SURGICAL SUITE MALIGNANT HYPERTHERMIA CART – MONTHLY CHECKLIST											
DRAWER 3												
	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEPT	OCT	NOV	DEC
1 – of each masks: #3, 4, 5 & pediatric: 1 small, 1 medium												
1 – Each of NG tubes: #12, 14, 16, 18												
1 – Irrigation tray with piston syringe for NG irrigation												
2 – Toomey irrigation syringe												
1 – Drip-catheter tray												
1 – Each 3-way irrigation foley catheters sizes #16, 18, 20, 24												
1 – Urine metered bag												
4 – Large clear bags for ice 4 – Small clear bags												
for ice												
1 – Bucket in room for ice												
2 – Esophageal temperature probes												
1 – Transducer kit (percutaneous)												
$1 - \frac{3}{4}$ sterile sheet (for wound)												
2 – Sterile jars												
3 – Cornwall syringes (extra)												



Title: Malignant Hyperthermia							
Document #: 6489	Issuing Authori	ty: BP Clinical Programs/Chief Nurse					
	nistration						
Last Revised Date: 11/29/20	19	Version Number: 2.1 (Current)					

	THE BRANTFORD GENERAL HOSPITAL MALIGNANT HYPERTHERMIA CART – MONTHLY CHECKLIST											
DRAWER 4	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEPT	ОСТ	NOV	DEC
1 – Each of paediatric & adult new circle tubing												
1 – Each of oral airways #6, 7, 8, 9, 10, 11												
1 – Each of CVP kits: Triple lumen 7 French, single lumen 16ga												
1 – Each Ambu bags: Adult & pediatric												
REFRIGERATOR	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEPT	ОСТ	NOV	DEC
Regular insulin - 1 each												
3 – Normal Saline 1000 mL IV bags												



Appendix F – Malignant Hyperthermia Critical Intervention Record

1	Brankferen		Aalignant Hyperthern tical Intervention Re			P	atient lo	dentification Lab	pel		
	Time:		Date:	(ircle: Ad	dult / F	ediatrio	: Weight:			
	Staff Assignm	nents:			Anesth	esiolo	gist:				
	Circulating No	urse:		Medication Nurse:							
	Dantrolene N	-		Cooling Nurse:							
	Other:			Other:							
•		AFAIT OF MAN			-		- Level Prov	- I I f			
Α			LIGNANT HYPERTHE				,				
	Signs of N Hyperth		Sudden/Unexpected Young Pa		c Arrest i	in	Irisn	nus or Masseter S Succinylcholii			
	□ Increased		Presume hyperka	ilemia a	nd initiat			sign of MH in ma			
	Trunk or li	mb rigidity	treatment					o rigidity, begin d			
	Masseter		Measure CK and J (urine myoglobin testing is					mergent procedu			
	spasm/tris		take 5-7 days)	periornico	anance, resource			non-triggering ag	ents; consider		
	Tachycard	ia/tachypnea	Consider dantrole	ene				olene			
	Acidosis		Usually secondary				Follow	v CK for 36 hours	(urine myoglobin		
	Increased	temperature	myopathy (e.g. m	uscular	dystroph	hy) 📊		ve in the Critical			
		 Resuscitation man prolonged 	y be dif	ficult and	· -		st 12 hours				
В				DIATE	ACTION	IS					
	 Call for hel Notify Surg Halt the pr 	p (and/or Cod geon/Anesthes	e Blue) iologist (if an emergent □ ers)	valve-m volume Use and high mi	nask with) esthesia r	ETCO2 machin tilatior	e ventila (e.g. 20	t 10 L/min or mo ring (3-4x norma ator immediately)-30 breaths/min	l minute and set for		
С			CIRCULATO	RY ACC	ESS ANI	D COO	LING				
	2 large bor	re IVs	Foley catheter i	nsertior	n						
	Cold NS fo	r IV infusion	Temperature m	onitorir	g						
			Apply ice to sur	face (di	scontinue	e when	temp le	ss than 38 degree	es Celsius)		
			Consider peritor	neal lav	age if ver	ry hype	rthermi	c			
D			DANTRO	LENE 2.	5 mg/kg	g rapid	IV				
			Use "Dantroler	ne Adm	inistrati	on Flo	wsheet	"			
				DR	UGS						
i	ndication	Drug	/Dose/Route	Tir	ne	Ti	me	Time	Time		
Meto	abolic Acidosis	sodium bicar									
	and/or	1-2 mEq/kg I	v/io								
hy	perkalemia	(maximum dose 50 n	nEq) Dose:								
Hy	perkalemia	calcium chlor	ide								
	10 mg/kg IV/IO										
		(maximum dose 200	omg) Dose:								
Hy	perkalemia	Regular insul	in 10 units IV								
	(ADULTS)	AND dextros	e 50% 50 mL IV								
	perkalemia	in 0.1 units/kg									
(P	EDIATRICS)	(maximum dose 10 u AND dextros (maximum dose 30 n	e 50% 4 mL/kg								
		IV Fluids									

Brant communit	iy ystem	Page 15 of 15
Title: Malignant Hyperthermi	ia	
Document #: 6489	Issuing Authorit Executive, Admin	y: BP Clinical Programs/Chief Nurse nistration
Last Revised Date: 11/29/20	19	Version Number: 2.1 (Current)

Appendix G – Malignant Hyperthermia Dantrolene Administration Flowsheet

Brant	Malignant Hype	rthermia	Patient	Identificat	tion Labe	1
Brantcommunity	Dantrolene Adm		Patient	laentincai	LION Labe	1
	Flowshe					
			ng/kg body weight			
Patient Weight Dose (m			ne of Reconstituted Solution	on (mL):	Number	of Vials
	n kg x 2.5 mg/kg =		in mg x 3 =	on (me).	Needed:	
1000		MIXIM	-			-
Reconstitute with 60 ml	of non-bacteriostati	c	Shake the vial for a	approxima	tely 20 se	conds or until
sterile water per 1 vial o	of 20 mg dantrolene s	odium	the solution is clea			
(concentration of recon	stituted solution is 0.3	33 mg/mL)	Inject rapidly into	the closest	t port to th	he patient
Inject the sterile water i	nto the vial of dantro	lene slowly	using aseptic tech	nique		
		ADMINIST	RATION			
Vial Number	Cumulative Dose	Partia	Vial Volume Needed	1	Time	Initials
(Check Box if WHOLE	of WHOLE Vials	(volume	needed – volume of # of	F		
20 mg Vial Given)	(mg / mL)		WHOLE vials) =			
Vial #1	20 mg / 60 mL					
Vial #2	40 mg / 120 mL					
Vial #3	60 mg / 180 mL					
Vial #4	80 mg / 240 mL					
Vial #5	100 mg / 300 mL					
Vial #6	120 mg / 360 mL					
Vial #7	140 mg / 420 mL					
Vial #8	160 mg / 480 mL					
Vial #9	180 mg / 540 mL					
Vial #10	200 mg / 600 mL					
Vial #11	220 mg / 660 mL					
Vial #12	240 mg / 720 mL					
Vial #13	260 mg / 780 mL					
Vial #14	280 mg / 840 mL					
Vial #15	300 mg / 900 mL					
Vial #16	320 mg / 960 mL					
Vial #17	340 mg / 1020 mL					
Vial #18	360 mg / 1080 mL					
Vial #19	380 mg / 1140 mL					
Vial #20	400 mg / 1200 mL					
Vial #21	420 mg / 1260 mL					
Vial #22	440 mg / 1320 mL					
Vial #23	460 mg / 1380 mL					
Vial #24	480 mg / 1440 mL					
Vial #25	500 mg / 1500 mL					
TOTAL VOLUME GIVEN (mL):	·				·
Administering Nurse Sig	nature Initials	Administe	ring Nurse Signature		Initial	s
L		I				